稀少遺傳性疾病治療市場:現狀分析與預測(2022-2028年)

Rare Genetic Disorders Treatment Market: Current Analysis and Forecast (2022-2028)

出版日期: 2023年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於罕見遺傳病的增加，預計罕見遺傳病治療市場在預測期內將以 11.9% 的複合年增長率增長。在全球範圍內，罕見遺傳病的發病率正在顯著增加。據GARD（遺傳和罕見病）信息中心2022年5月的數據，十分之一的美國人（3000萬人）患有罕見病，已知的罕見病約有7000種。此外，根據GlobalGenes 2021年9月更新的數據，全球有超過4億人受到罕見疾病的影響。80%的罕見疾病已被確定具有遺傳起源。

為了更好地了解罕見遺傳性疾病治療行業的市場採用情況，我們根據其在以下國家/地區的全球分佈對市場進行了分析：北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太地區其他地區）、世界其他地區由於人們對罕見疾病的認識提高、醫療保健支出增加以及有利的政府政策，預計亞太地區市場在預測期內將出現最高增長率。治療方法的可用性也推動了市場的增長。例如，根據世界經濟論壇稱，亞太地區約有 2 億人患有罕見疾病。

Rare genetic disorders, also known as orphan diseases, are defined as conditions that affect fewer than 200,000 people in the United States or fewer than 5 in 10,000 people in the European Union. While these diseases are individually rare, collectively they affect millions of people worldwide. The orphan drug market has been driven by government incentives, such as expedited regulatory review and approval processes, tax credits, and extended periods of market exclusivity.

The Rare Genetic Disorders Treatment Market is expected to grow at a strong CAGR of 11.9% during the forecast period owing to the rise in the incidences of rare genetic diseases. Globally the incidence of rare genetic diseases is increasing tremendously. According to the Genetic and Rare Diseases (GARD) Information Center in May 2022, 1 in 10 Americans (or 30 million people) have a rare disease, and there are approximately 7,000 known rare diseases. Moreover, as per data updated in September 2021 by the "GlobalGenes", more than 400 million people worldwide are impacted by rare diseases. 80% of rare diseases have been identified with genetic origins.

Based on application, the market is segmented into cancer, neurological disorders, cardiovascular diseases, metabolic disorders, hematology diseases, and others. The cancer segment held a dominant share of the market in 2021 mainly due to the surge in the incidences of rare genetic cancers and advances in genomic sequencing technology for their early diagnosis. In addition to this, several pharmaceutical players are actively investing in research and development to identify new drug candidates, thus having a positive impact on the segment growth in the coming years. For instance, in November 2022, Unravel Biosciences entered into a collaboration with Spanios to discover therapeutic targets for rare cancer. Under the partnership, Unravel Biosciences will leverage its artificial intelligence (AI) gene network-based computational model for predicting the therapeutic compounds and underlying new targets depending on the transcriptomic information.

By drug type, the market is bifurcated into biologics & biosimilars, and non-biologics. The biologics & biosimilar segment held a dominant share of the market in 2021 owing to their high specificity towards the disease. Biologics & biosimilars drugs are increasingly being used for the treatment of rare genetic disorders, including hematology diseases. Biologics are drugs that are derived from living cells, and include proteins, antibodies, and other complex molecules. Biosimilars are similar to biologics, but are developed after the patent for the original biologic drug has expired. Several biologics have beend approved for the management of rare genetic disorders including Rituximab, Adalimumab, zynteglo, and others. Apart from this, rising product pipelines and their encouraging response in clinical trials is also suggesting positive future growth of this segment. For instance, in 2020, Regenreon Pharmaceuticals announced encouraging results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP).

On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The online pharmacy is expected to witness high CAGR during the forecast period. Online pharmacies are also gaining considerable momentum in the market owing to their convenience. Consumers can order medications from the comfort of their own homes and have them delivered directly to their doorsteps. This is especially beneficial for those who live in rural areas or have mobility issues, as it eliminates the need for them to travel to a physical pharmacy. Moreover, online pharmacies often offer lower prices than traditional brick-and-mortar pharmacies due to lower overhead costs. In addition, online pharmacies may offer discounts, promotions, and loyalty programs to attract and retain customers. According to a survey conducted by the National Community Pharmacists Association, 61% of respondents said that cost was the primary reason they chose to use an online pharmacy.

For a better understanding of the market adoption of the rare genetic disorders treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The Asia Pacific market is expected to register highest growth rate in the forecast period due to an increase in awareness regarding rare diseases, rising healthcare expenditure, and favorable government policies. Moreover, the surge in the incidences of rare diseases in the region and the availability of therapies is also driving the growth of the market. For instance, According to the World Economic Forum, around 200 million people are living with rare diseases in Asia Pacific.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Bristol Myers Squibb; Sanofi; Novartis AG; AbbVie Inc.; GlaxoSmithKline Plc; Amgen Inc.; and Johnson & Johnson Inc.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Rare Genetic Disorders Treatment Market
2.2. Research Methodology of the Rare Genetic Disorders Treatment Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL RARE GENETIC DISORDERS TREATMENT MARKET COVID-19 IMPACT

6 GLOBAL RARE GENETIC DISORDERS TREATMENT MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY APPLICATION

7.1. Cancer
7.2. Neurological Disorders
7.3. Cardiovascular Diseases
7.4. Metabolic Disorders
7.5. Hematology Diseases
7.6. Others

8 MARKET INSIGHTS BY DRUG TYPE

8.1. Biologics & Biosimilars
8.2. Non-Biologics

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

9.1. Hospitals Pharmacy
9.2. Online Pharmacy
9.3. Retail Pharmacy

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. United States
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. France
- 10.2.3. U.K.
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia Pacific
10.4. Rest of World